ライフサイエンスコーパス: viral myocarditis

1 inflammation and outcome in a mouse model of viral myocarditis.

2 To review how autoimmunity is induced in viral myocarditis.

3 M were observed in the subgroup (n=130) with viral myocarditis.

4 is a characteristic of both human and mouse viral myocarditis.

5 t, and is a potential therapeutic target for viral myocarditis.

6 specific T cell responses during subclinical viral myocarditis.

7 CVB3 is a primary cause of viral myocarditis.

8 ces in IFN antagonism to the pathogenesis of viral myocarditis.

9 Four patients had probable viral myocarditis.

10 +) T regulatory cells, which protect against viral myocarditis.

11 he myocardial inflammatory response in acute viral myocarditis.

12 response during the initial phases of acute viral myocarditis.

13 nvestigate non-immune-mediated mechanisms of viral myocarditis.

14 re inflammation and injury, also occurred in viral myocarditis.

15 lymphoid cell compartment, are protective in viral myocarditis.

16 Viral myocarditis affects an estimated 5 to 20% of the h

17 222 consecutive patients with biopsy-proven viral myocarditis and CMR were enrolled.

18 8-52] years) with a history of biopsy-proven viral myocarditis and drug-refractory VT; 5 patients pre

19 n mediating cardiac injury in the setting of viral myocarditis and is the first demonstration that ca

20 idence that IFN-beta can be a determinant of viral myocarditis and reovirus disease.

21 ew insights into the innate host response to viral myocarditis and the various therapeutic strategies

22 thogenic processes of coxsackievirus-induced viral myocarditis and to screen antiviral therapeutics f

23 subanalysis in 130 adult patients with acute viral myocarditis and viral prodrome within 2 weeks from

24 usion injury, sepsis, chronic heart failure, viral myocarditis, and cardiac allograft rejection.

25 f sepsis, seven patients with a diagnosis of viral myocarditis, and five control patients without cli

26 myocardial ischemia and reperfusion, sepsis, viral myocarditis, and immune rejection.

27 ate the long-term mortality in patients with viral myocarditis, and to establish the prognostic value

28 Long-term mortality of viral myocarditis, as well as potential risk factors for

29 n only rarely develop life-threatening acute viral myocarditis (AVM), given that the causal viral inf

30 therapeutic agent for the treatment of acute viral myocarditis during the viremic phase.

31 Viral myocarditis follows a fatal course in approximatel

32 Viral myocarditis has been proposed to be divided into 3

33 ong been considered the most common cause of viral myocarditis; however, we previously demonstrated b

34 IFN-beta) is critical for protection against viral myocarditis in mice.

35 he treatment of viral disease in general and viral myocarditis in particular.

36 been speculated that ARVD/C is a sequela of viral myocarditis in some patients, and the role of the

37 e an attractive therapeutic approach against viral myocarditis in the future.

38 endocardial fibroelastosis is a sequela of a viral myocarditis, in particular of that due to mumps vi

39 V-1 model will enable fundamental studies of viral myocarditis, including IFN-gamma modulation as a t

40 Using this novel model for viral myocarditis induced with Theiler's murine encephal

41 Viral myocarditis is a disease with a high morbidity and

42 Viral myocarditis is a life-threatening illness that may

43 Viral myocarditis is among the most common causes of hea

44 Viral myocarditis is an important cause of human morbidi

45 Viral myocarditis is an important human disease, and reo

46 Viral myocarditis is an important human disease, with a

47 de range of clinical symptoms, biopsy-proven viral myocarditis is associated with a long-term mortali

48 esis of chronic dilated cardiomyopathy after viral myocarditis is complex and determined by host and

49 Viral myocarditis is remarkably common, being detected i

50 A major causative agent for viral myocarditis is the B3 strain of coxsackievirus, a

51 e disorders and may be beneficial in chronic viral myocarditis once virus is cleared.

52 hs in the understanding of the etiologies of viral myocarditis or dilated cardiomyopathy (DCM).

53 ackievirus B3 (CVB3) is a causative agent of viral myocarditis, pancreatitis, and meningitis in human

54 ), an important human causative pathogen for viral myocarditis, pancreatitis, and meningitis, has evo

55 Acute viral myocarditis progresses through several stages, inc

56 Viral myocarditis remains a prominent infectious-inflamm

57 sclerosis, acute coronary syndromes, stroke, viral myocarditis, sepsis, ischemia/reperfusion injury,

58 immunity signal transducer IRAK4 exacerbates viral myocarditis through inhibition of interferon produ

59 Using a reovirus murine model of viral myocarditis, we characterized and targeted apoptos

60 The benefits of TIMP-1 blockade in treating viral myocarditis were confirmed by administering, to wi

61 unction, we treated a patient with fulminant viral myocarditis with the interleukin-1 receptor blocki

62 s modulate heart failure pathogenesis during viral myocarditis, yet their identities and functions re